| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2015041534 |
| Title |
P90Rsk In Combination with Raf/Erk/Mek. |
| Abstract |
The current disclosure relates to pharmaceutical combinations and compositions useful in the treatment of certain types of cancer. The disclosure also relates to method of treatment these certain types of cancer. In particular, the disclosure relates to the combined use of an inhibitor of p90RSK and an inhibitor of another protein of the MAPK/ERK-pathway in the treatment of KRAS-, NRAS-or BRAF-mutated cancer, in particular in NRAS mutated melanoma. |
| Applicant(s) |
Stichting Het Nederlands Kanker Instituut |
| United States Patent and Trademark Office (USPTO) |
| Patent ID |
US8426568 |
| Title |
Rhamnose Substituents of Sl0101 and Therapeutic Use of Thereof. |
| Representative Drug(s) |
D02ABC |
Drug Info
|
N.A. |
[1] |
| Patent ID |
US7371750 |
| Title |
Compounds and Compositions As Protein Kinase Inhibitors. |
| Representative Drug(s) |
D0BN4A |
Drug Info
|
N.A. |
[1] |
| Patent ID |
US9040673 |
| Title |
Synthesis and Identification of Novel Rsk-Specific Inhibitors. |
| Patent ID |
US7435819 |
| Title |
4,5,6,7-Tetrahydro-[1,2]Dithiolo[4,3-C]Pyridine-3-Thione Compounds. |
